pioneered products of sabinsa- sep 16, 2011
TRANSCRIPT
© Sabinsa Corporation 2011| www.sabinsa.com
National Seminar – Pharma Eminence 2011
A presentation from Sami Labs Ltd. / Sabinsa Corp.
Date: September 16, 2011
By:
Dr. Muhammed Majeed
Group Chairman,
Sami & Sabinsa Group of Companies
Presented by:
Dr. S. Natarajan
Executive Vice President, R&D
Sami Labs Ltd., Bangalore
© Sabinsa Corporation 2011| www.sabinsa.com 2
© Sabinsa Corporation 2011| www.sabinsa.com
Edkal CorporationIndia / USA
SabinsaSouth Africa
SabinsaChina
SabinsaJapan
AFI’sUSA
SabinsaUSA
NJ & Utah
SabinsaVietnam
SabinsaEurope (Germany)
Hanbury FZEU.A.E.
Organica Aromatics
India
ClinWorld Inc.India / USA
SAMI LABSINDIA
SabinsaPhilippines
SabinsaAustralia
Global Presence and Group Companies
Sami DirectIndia
3
© Sabinsa Corporation 2011| www.sabinsa.com 4
© Sabinsa Corporation 2011| www.sabinsa.com 5
• BioPerine is a patented standardized extract obtained from black pepper, containing not less than 95% Piperine.
• A clinically proven natural bioavailability enhancer for nutrients1
1 Summaries of clinical studies are available at: www.bioperine.com
U.S. PATENTS # 5536506 (1996), # 5744161 (1998)# 5972382 (1999),# 6054585 (2000)
INTERNATIONAL PATENTS:European Patent # EP 0810868 (2001)Japan: # JP 3953513 (2007)Canada: # CA 2247467 (2007)
(Mercy Medical Centre, NY)
© Sabinsa Corporation 2011| www.sabinsa.com 6
BioPerine® increased the absorption of co-administered beta-carotene in human volunteers
(Mercy Medical Centre, NY)
© Sabinsa Corporation 2011| www.sabinsa.com 7
Efficacy of BioPerine (5 mg) on the bioavailability of
Vitamin B6 absorption in human volunteers
© Sabinsa Corporation 2011| www.sabinsa.com 8
Mean serum CoQ10 values during supplementation of 120 mg of CoQ10 with and without 5 mg of piperine
© Sabinsa Corporation 2011| www.sabinsa.com
BioPerine® Enhances Bioavailability of Resveratrol-
University of Wisconsin Study
9
BioPerine® significantly improves the bioavailability of ResveratrolPlasma exposure for Resveratrol increses by 255%Cmax for Resveratrol increases by a phenomenal 1544%Economic impact of such findings very substantial in bringing down the cost of nutrients precipitouslyStudies Directed at Neuroendocrine cancer inhibition by ResveratrolPhase I studies are underway at University of WisconsinFindings have an impact on other nutrients such as Silbinol®Molecular Nutr Food Res., 2011, 55, In Press
© Sabinsa Corporation 2011| www.sabinsa.com 10
L(+)-SELENOMETHIONINE (USP)
O
OH
NH2
H3 C
Se
www.seleniumselect.com
© Sabinsa Corporation 2011| www.sabinsa.com 11
• L(+)-Selenomethionine : Stereospecific natural form of bioavailable selenium
• Sami Labs - Received Basic Drugs Award (1994) for pioneering manufacture in India; is the largest manufacturer of L(+)-Selenomethionine.
NATIONAL QUALITY AWARD
(BASIC DRUGS, 1994)
© Sabinsa Corporation 2011| www.sabinsa.com 12
FDA allowed qualified health claim:
“Selenium may reduce the risk of certain types of cancers”
SELENIUM IN HEALTH
Supplemental selenium daily dose is generally : 50-200 mcg
High dose selenium (L(+)-Selenomethionine) is being studied as a treatment for various types of cancer.
© Sabinsa Corporation 2011| www.sabinsa.com 13
Potential Role in Clinical Practice
Selenium
Cancer Prevention
Arthritis/inflammatory
diseases
Diabetes Support
Cardiovascular Health
Beneficial effectsin HIV infection
Immunity & Resistance to
Infections
© Sabinsa Corporation 2011| www.sabinsa.com 14
SelenoForce®
Source of selenium with greater efficacy in breast cancer prevention
US Patent # 7014874 (2006)
© Sabinsa Corporation 2011| www.sabinsa.com 15
METHYL SELENOCYSTEINE
Naturally found in garlic and cruciferous vegetables
Sami Labs manufactures the stereospecific L natural form
US Patent 6794537 - Sami Labs (2004) - Process PatentUS Patent 6982273 - Sami Labs (2006) -Human & veterinary use patent
© Sabinsa Corporation 2011| www.sabinsa.com 16
US Patent 8003614- Sami Labs (2011)-Dipeptides Containing Seleneium- Bioavailability-Pharma-Cosmeceuticals
Applications
Selenium Containing Peptides
© Sabinsa Corporation 2011| www.sabinsa.com
Setting the Standard….
17
© Sabinsa Corporation 2011| www.sabinsa.com 18
(Coleus forskohlii Extract)
US 5804596 (1998)EP 0977564 (2005)CA 2281562 (2008)
Role in enhancing lean body massand in the treatment of mood disorders
OCH
CH2
OCOCH3
OH CH3
H
OH
OH O
CH3
H3C
CH3
Forskolin
© Sabinsa Corporation 2011| www.sabinsa.com 19
ForsLean®, manufactured by
a proprietary process.
It is a standardized extract
from the roots of the Coleus
forskohlii plant, the only
known plant source of the
Forskolin.
Nutracon Award, 2001
Achievements & Recognitions
© Sabinsa Corporation 2011| www.sabinsa.com 20
Achievements & Recognitions
US Patent # 5804596, won the Thomas Alva Edison Patent Award (R & D Council, NJ USA) on November
11, 2004
© Sabinsa Corporation 2011| www.sabinsa.com 21
1. Open field study (8 weeks) with 6 overweight women subjects. Dr. A. Conte, USA2. Open-field study (6 months) with sixteen obese subjects: Dr. Asano, Japan3. Pilot clinical efficacy and safety study, 19 women subjects, randomized , double blind placebo controlled : University of Memphis TN, USA4. Preclinical toxicology evaluation - CBPRC, Bombay5. 60 subject clinical efficacy study – CBPRC, Bombay6. 24 subject body composition evaluation and body weight Northern Michigan University, USA7.Double-blind placebo controlled study, 30 obese/overweight subjects Kansas State University, USA 8. 60 subject clinical efficacy study – Completed– at Manipal9. 6 month feeding/toxicity study- Completed
10. Micronuclei and dose effects studies- Completed
11. Bone Density and Hormonal Levels Study (3months) with 24 women subjects –Completed Dr. Pankaj Gandhi Hospital, Mumbai
12.Hormonal Study (3months) with 30 male subjects- Completed Kasturba Medical College,Manipal
Clinical Studies
© Sabinsa Corporation 2011| www.sabinsa.com 22
•Lean Body Mass refers to the sum of the weight of your bones, muscles and organs... basically the sum of everything other than fat in your body
• Measurable
•A Better Description of Obesity Conditions
LEAN BODY MASS
© Sabinsa Corporation 2011 | www.sabinsa.com
23
Before After 4 weeks After 8 weeks
-10
-8
-6
-4
-2
0
2
4
6
8
10Meanweight loss(lbs)
Mean bodyfat (%)
Mean leanbody mass(%)
Effects on Body Weight, Body Fat and Lean Body
Mass
%
10
8
6
2
0
-2
-4
-6
-8
lbs
N = 6
4
-10
Open field study, 6 overweight women subjects, 500 mg ForsLean corresponding to 50 mg forskolin/day for 8 weeks
Majeed et al, Nutracos, Feb 2006, Page 2
© Sabinsa Corporation 2011| www.sabinsa.com 24
Exercise, Supplements and ObesityExercise, Supplements and Obesity
© Sabinsa Corporation 2011| www.sabinsa.com 25
The Ohio State University Comprehensive Cancer Center is conducting a study on Forskolin’s effect on Chronic Myelogenous Leukemia (CML).
Early results on CML patient cells both in culture and in mice showed that forskolin reduced the cancer cells’ ability to grow up to 90 percent.
Anti Cancer Application
© Sabinsa Corporation 2011| www.sabinsa.com 26
CURCUMIN C3 COMPLEX®
Source: Curcuma longa (Turmeric)
Active components: Curcuminoids
Antioxidant, Anti-inflammatory support, Immune support.
Plant part used: Roots
U.S. PATENT US 5861415 (1999)European Patent EP 0839037 (2002)
© Sabinsa Corporation 2011| www.sabinsa.com 27
© Sabinsa Corporation 2011| www.sabinsa.com 28
The first book to comprehensively list the medicinal claims of Curcuminoids was published by SABINSA in
1993
© Sabinsa Corporation 2011| www.sabinsa.com
Therapeutic potential of Curcumin
HIV replication
HIV Replication
Curcumin C3 Complex®
ChemopreventiveSkin, liver, colon, stomach
Diabetes
Cardiovascular diseases
Cholesterol, platelet aggregation, inhibition of
smooth muscle cell proliferation
Arthritis
Anti-inflammatory
Chemotherapeutic
Antioxidant
Lung fibrosis
Nephrotoxicity
Cardiotoxicity Wound healing
Cataract formation
Antiangiogenic
Multiple sclerosis
Alzheimer disease
Gall-stones formation
Adopted from Dr.Bharat Aggarwal, MD Anderson Cancer Research Center, Texas
29
© Sabinsa Corporation 2011| www.sabinsa.com 30
Curcumin and its Multi-targets
www.curcuminresearch.org
© Sabinsa Corporation 2011| www.sabinsa.com 31
Curcumin potentiates the effect of paclitaxel by suppressing the metastasis of the human breast cancer to the lung in mouse xenograft model
Curcumin potentiates the effect of paclitaxel by suppressing the metastasis of the human breast cancer to the lung in mouse xenograft
model
Clinical Cancer Research 2005 Oct 15;11(20):7490-8
© Sabinsa Corporation 2011| www.sabinsa.com 32
Disease Investigator Institution
Multiple myeloma Saroj Raj-Vadhan, MD UTMDACC, USA
Pancreatic cancer Razelle Kurzrock, MD UT MDACC, USA
Pancreatic cancer Rami Ben Yosef, MD Ichilov, Israel
Melanoma Christopher D. Lao, MD University of
Michigan, USA
Colon Cancer Ernie Hawk, MD National Cancer Institute,
UK
Colon Cancer Dean Brenner, MD University of
Michigan, USA
Colon Cancer William P Steward, MD University of Leicester, UK
Alzheimer’s Disease Milan Fiala, MD UCLA, USA
Safety Studies Dean Brenner, MD University of
Michigan, USA
Myelodysplastic syndrome Azra Raza, MD University Mass., USA
Gall Bladder Cancer V.K.Shukla Banaras Hindu
University, India
Gall Bladder Cancer Nihar Rajan Das AIIMS, India
Ongoing Clinical Trials with Curcumin
Adopted from Dr.Bharat Aggarwal, MD Anderson Cancer Research Center, Texas
© Sabinsa Corporation 2011| www.sabinsa.com 33
© Sabinsa Corporation 2011| www.sabinsa.com 34
Source: Boswellia serrata (Indian frankincense, olibanum)
Active components: Beta-Boswellic Acids
Nutraceutical applications: Supports the management of inflammation.
Plant part used: Exudate (gum resin)
Form in which supplied: Standardized extract (powder)
BOSWELLIN
© Sabinsa Corporation 2011| www.sabinsa.com 35
© Sabinsa Corporation 2011| www.sabinsa.com
The FOUR major identified pentacyclic triterpenoids in Boswellin® are…
β -Boswellic acid Acetyl- β -Boswellic acid11-keto- β -Boswellic acidAcetyl -11 –keto –β -Boswellic acid
BoswellinBoswellin®® - - ChemistryChemistry
36
© Sabinsa Corporation 2011| www.sabinsa.com
-Boswellic Acid Acetyl--Boswellic Acid
11-Keto--Boswellic Acid Acetyl-11-Keto--Boswellic Acid
Sabinsa Corporation
OH
HOOCH
H HOOC
AcO
O
HHOOC
HO
O
HHOOC
AcO
O
Chemistry of Boswellic Acids
37
© Sabinsa Corporation 2011| www.sabinsa.com 38
Salient Features of Boswellin
Sami Labs/Sabinsa Corporation pioneered the introduction of standardized Boswellia serrata extract to global markets
Correctly standardized for boswellic acids (method submitted to the United States Pharmacopoeia for monograph development)
© Sabinsa Corporation 2011| www.sabinsa.com 39
Promising Clinical trials for the following indications are reported in literature:
Rheumatoid arthritis OsteoarthritisChronic colitisUlcerative colitisCrohn's diseaseBronchial asthmaPeritumoral brain edemas*
* European Union: orphan drug application exists for this indication
Anti-inflammatory Applications of Boswellic acids
Ref: Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr. 2002;152(15-16):373-8. Review. German
© Sabinsa Corporation 2011| www.sabinsa.com 40
POLICOSANOL
Policosanol is a mixture of fatty alcohols derived from waxy extract of sugarcane.
Policosanol is reported to support healthy blood lipid levels and cardiovascular health
Patents:US 7217546 (2007)IN 229695 (2009)
© Sabinsa Corporation 2011| www.sabinsa.com 41
Clinical Studies
A double-blind placebo controlled study was conducted using Sabinsa’s Policosanol derived from Indian Sugarcane to investigate
– the efficacy of Policosanol vs. Atorvastatin for the treatment of Hyperlipidaemia.
© Sabinsa Corporation 2011| www.sabinsa.com 42
Decrease in Cholesterol Levels
Details Policosanol Atorvastatin
%
Mean 16.1116.11 19.66
SEM 1.85 2.59
© Sabinsa Corporation 2011| www.sabinsa.com 43
Details Policosanol Atorvastatin
%
Mean 33.7433.74 35.61
SEM 3.22 4.19
Decrease in Triglyceride Levels
© Sabinsa Corporation 2011| www.sabinsa.com 44
Details Policosanol Atorvastatin%
Mean 20.9120.91 23.87
SEM 3.32 2.69
Decrease in Cholesterol / HDL Ratio
© Sabinsa Corporation 2011| www.sabinsa.com 45
ESR
0
5
10
15
20
25
Base LineFinal
Policosanol Atorvastatin
Details ESR
%
Details ESR
% BASELINE
FINAL VISIT
BASELINE
FINAL VISIT
Mean 23.10 16.33 29.32 Mean 17.26 18.53 7.36
SEM 2.65 1.60 4.33 SEM 2.67 4.24 5.04
ESR, an early marker of inflammation, significantly decreased with Policosanol but increased by 7.36% with Atorvastatin.
Policosanol Atorvastatin
© Sabinsa Corporation 2011| www.sabinsa.com 46
Clinical Trials
• Policosanol compared favorably with Atorvastatin at improving the serum lipid profile.
• Policosanol was well tolerated and no drug-related adverse drug reactions were observed.
• Policosanol is a safe and effective supplement
for lowering of bad cholesterol levels and can be used to lower several cardiovascular disease risk factors.
© Sabinsa Corporation 2011| www.sabinsa.com 47
• Gugulipid is a patented standardized extract obtained from Commiphora mukul (wightii) gum resin (Guggul), containing not less than 2.5% guggulsterones.
• Clinically proven to support cardiovascular health.
• Guggul has been traditionally used in Ayurveda in the management of obesity and inflammation.
1 Summaries of clinical studies are available at: www.gugulipid.com
Commiphora mukul tree
US Patent: US 6436991 (2002)
© Sabinsa Corporation 2011| www.sabinsa.com 48
Lipid disordersCardiovascular health Obesity Arthritis and inflammation Thyroid stimulation Acne management support
Potential Roles in Clinical Practice
© Sabinsa Corporation 2011| www.sabinsa.com 49
Sabinsa, USA sponsored an IND for Gugulipid®. “Randomized, Double Blind, Placebo Controlled Trial
Evaluating the safety and Efficacy of GUGULIPID in Americans with Hypercholesterolemia”.
Dept. of General Internal Medicine.University of Pennsylvania 9 Penn Tower, 3400 SpruceSt,. Philadelphia, USA. 1st Publication: Gugulipid® for the treatment of
Hypercholesteremia.A randomized trial. JAMA, August 13, 2003,
Vol. 290 No. 6
2nd Presentation: Metabolic Effects of Gugulipid®. 10th Annual symposium on Complementary
Healthcare, Royal Collage of Physicians, London, UK.
Clinical efficacy study: Mercy Medical Center, Bronx, New York
Dr. Edward Norkus Double Blind Cross over study-ongoing
Pharmacology & Clinical Trials
© Sabinsa Corporation 2011| www.sabinsa.com 50
Comprehensive indices of cardiovascular health were measured:
Oxidative stress
C-reactive protein (CRP)
Levels of uric acid
Lipoprotein (a)
Role in Cardiovascular Health
Summary of results
© Sabinsa Corporation 2011| www.sabinsa.com 51
RESULTS OF RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED CROSSOVER STUDY
Active therapy: Gugulipid® (75 mg guggulsterones daily dose, 12 weeks, 30 volunteers )
0 0.5 1 1.5 2
SerumMDA
(mg/dl)
Serum hs-CRP
(mg/dl)
Placebo
Gugulipid
hs-CRP: high-sensitivity C-reactive protein, marker of oxidative stress - associated with inflammationMDA: Malondialdehyde, marker of oxidative stressNo dermatologic hypersensitivity observed during treatment
(Mercy Medical Center, NY, October 2004)
© Sabinsa Corporation 2011| www.sabinsa.com 52
RESULTS OF RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PARALLEL DESIGN STUDY ON Lp(a) levels
Active therapy: Gugulipid® (75 mg (standard dose, SDG) or 150 mg (high dose, HDG)
guggulsterones daily, 8 weeks, 42 volunteers with elevated Lp(a) )
-5
-7
1
-8-7-6-5-4-3-2-1012
SDG HDG Placebo
Mean
perc
en
tag
e c
han
ge i
n L
p(a
) le
vels
fr
om
Base
lin
e o
f 0.7
1 m
icro
mol/
L
Szapary, PO et al. JAMA, Aug 13, 2003, 290(6): 765-772
© Sabinsa Corporation 2011| www.sabinsa.com 53
Source: Garcinia cambogia (Fam. Clusiaceae)
Plant part used: Fruits
Active constituents : (-) Hydroxycitric acid, (-)HCA, Garcinol
Nutraceutical benefits: Weight management support
Patents: AU 773081 (2004), NZ 518116 (2005), US 7063861 (2006), EP 1254209 (2006), and JP 4205943 (2008)
© Sabinsa Corporation 2011| www.sabinsa.com 54
© Sabinsa Corporation 2011| www.sabinsa.com
Ocufors Eye Drops – for Glaucoma
• First natural drug to go through full fledged clinical documentation to obtain a drug approval
55
© Sabinsa Corporation 2011| www.sabinsa.com 56
Normal visionSame scene as viewed
by a person with glaucoma
Vision of a Glaucoma patient
Patents Granted:USA : US 6960300 (2005); Singapore: SG 121197 (2008)Mexico : MX 260326 (2008); South Africa: ZA 2006/01898 (2008)
Application in Glaucoma
Ocufors – from Coleus forskohlii
© Sabinsa Corporation 2011| www.sabinsa.com
Ocufors™ Eye drop solutions for Glaucoma Treatment
Ocufors™, a patented ophthalmic solution containing 1-2% forskolin, for the treatment of glaucoma
First time the Government of India has approved a product developed from natural sources for use as a pharmaceutical grade drug
A stable, water-soluble forskolin solution shown in clinical trials to be 30 % more effective than the most popular glaucoma treatment in the world market today
57
© Sabinsa Corporation 2011| www.sabinsa.com 58
Forskolin TimololIn
tra
oc
ula
r p
res
su
re0
-10
5
-6-6.4*
-4.9
-3.2
*p<0.05
Right eye
Left eye
IND # 3305/115Human Study Completed and drug status granted
Summary Data
© Sabinsa Corporation 2011| www.sabinsa.com
First NDA – MF 6746 received in 2006 from Drug Control General of India for Forskolin eye drops in the treatment of Open Angle Glaucoma
59
© Sabinsa Corporation 2011| www.sabinsa.com 60
First natural drug to go through full fledged clinical documentation to obtain a
drug approval
© Sabinsa Corporation 2011| www.sabinsa.com 61
The solution for Psoriasis“An autoimmune disorder with not
much therapy in modern medicine”
Sornip – from Boswellia serrata(Patented by Sami Labs & marketed by Cipla)
© Sabinsa Corporation 2011| www.sabinsa.com
BASELINE VISIT FINAL VISIT
An open Multicentric Phase III clinical trial to investigate the efficacy and safety of a natural compound formulation for management of Psoriasis - study has been successfully completed and approved by DCGI.
The Psoriasis Trial
62
© Sabinsa Corporation 2011| www.sabinsa.com 63
Psoriasis
Before After
© Sabinsa Corporation 2011| www.sabinsa.com
BASELINE VISIT FINAL VISIT
Psoriasis Trial
Patents Granted:South Africa: ZA 2007/0694 (2007);Singapore: SG
136165(2009);Russia: RU 2366412 (2009); New Zealand: NZ
552027 (2010).64
© Sabinsa Corporation 2011| www.sabinsa.com 65
© Sabinsa Corporation 2011| www.sabinsa.com 66
• LactoSpore is a lactic acid bacillus preparation in the form of a light colored powder manufactured and distributed by Sabinsa.
• The source of Lactic acid bacillus was originally known in literature as Lactobacillus sporogenes.
• It is also known as Bacillus coagulans.
• Lactobacillus sporogenes produces only L(+) Lactic acid.
Sabinsa provides LactoSpore® of the following strengths 6 Billion spores/g 15 Billion spores/g
LACTOSPORE®EC - Under development
© Sabinsa Corporation 2011| www.sabinsa.com 67
LactoSpore®
An ideal probiotic for the following reasons:
Room temperature stable Naturally microencapsulated for stability and
ease of processing Proliferates within the GI tract Produces L(+) Lactic acid only Aids in protein, lipid and carbohydrate digestion Compatible with nutrients and antibiotics Not artificially made resistant Japanese FDA approved probiotic
© Sabinsa Corporation 2011| www.sabinsa.com 68
LactoWise® a Synbiotic, is a proprietary composition comprising of beneficial human intestinal microorganisms and a source of dietary fiber for promoting gastrointestinal health.
The composition includes
• Bacillus coagulans, a probiotic marketed by Sabinsa Corporation, US under the brand name LactoSpore®.
• Soluble Fenumannans from the dietary fibers FenuFibers®, from Sabinsa Corporation US.
© Sabinsa Corporation 2011| www.sabinsa.com 69
© Sabinsa Corporation 2011| www.sabinsa.com 70
TETRAHYDROCURCUMINOIDS(White Turmeric)
Skin lightening effects ( inhibition of melanogenesis)
Antioxidant action
Anti-inflammatory action
COLOR FREE compounds derived from yellow Curcuminoids extracted from Curcuma longa (turmeric) roots.
Patents: US 6653327 (2003), EP 1171144 (2007), AU 2006235807 (2008), NZ 514884 (2008), EP 1328263
(2009)
© Sabinsa Corporation 2011| www.sabinsa.com 7171
Freeze dried Powder from tender green coconut water
A natural reservoir of nutrients and growth factors to support healthy cell growth , nutrition, hydration and cell rejuvenation
Proprietary process to retain optimum bio-potency
Th
e N
ou
rish
men
t F
acto
r®
Patented: US 7300682 (2007) and EP 1341547 (2006)Affirmed GRAS for Food and Beverage Applications 71
© Sabinsa Corporation 2011| www.sabinsa.com 72
(Tetrahydropiperine)
Patented: GB 2380675 (2003) US 6849645 (2005) and JP 4098985 (2008)
Prepared by a patented proprietary process from black pepper Acts as a skin permeation enhancer for other active ingredients in formulations
© Sabinsa Corporation 2011| www.sabinsa.com 73
Transdermal Absorption Study with
Betamethasone Dipropionate (BMDP)
THP increased permeation of BMDP, when combined with THP as compared to BMDP application alone. Reference: Research Report, Sami Labs Ltd. (April 2000)
© Sabinsa Corporation 2011| www.sabinsa.com 74
Winner of 2005 Thomas Alva Edison Patent Award –NJ R&D Council
© Sabinsa Corporation 2011| www.sabinsa.com 75
Ayurveda’s Original Rasayana
ORAC Dense Phytonutrient
© Sabinsa Corporation 2011| www.sabinsa.com 76
Recognized in Ayurvedic tradition of Indian medicine, Amalaki or Amla and is known for its traditional used in hair care and skin care.
Saberry® is a light colored and water soluble powder obtained from the fruits of Emblica officinalis or Amla.
© Sabinsa Corporation 2011| www.sabinsa.com 77
Salient Features of Saberry®
100% Natural New biomarker β Glucogallin, in Amla
extracts Novel extraction technology to preserve
the efficacy International Patent Pending Published in Journal of Agricultural and
Food Chemistry, Volume 57(1) 2009 GRAS Affirmed
© Sabinsa Corporation 2011| www.sabinsa.com 78
© Sabinsa Corporation 2011| www.sabinsa.com 79
In addition to the active Boswellic acids, Boswellin® PS* also contains Polysal which contributes to its immediate anti-inflammatory action.
Boswellin® PS* is standardized to contain:
AKBBA 10% Total Identified Boswellic Acids 20% Total Organic Acids 35%
* Patent pending
Boswellin®PS*
© Sabinsa Corporation 2011| www.sabinsa.com
CHILITENOIDS®
• Chilitenoids® are Sabinsa’s standardized extract obtained from dried fruits of Capsicum annuum.
• Chilitenoids® are natural xanthophyll carotenoids with a bright red color.
• Chilitenoids® are available as Soft extract containing minimum 5% Capsanthin.
• Sabinsa’s Chilitenoids® are stable.
Capsanthin
80
© Sabinsa Corporation 2011| www.sabinsa.com
Chilitenoids® - Specification
Content of Total Carotenoids : Not less than 10.0%
Content of Capsanthin : Not less than 5.0%
Color value : Between 1x105 to 1.5x105
81
© Sabinsa Corporation 2011| www.sabinsa.com
Applications
Chilitenoids® can find applications
As a Nutraceutical, for antioxidant and heart health support
As a Natural color in food applications
As a Natural color in Color Cosmetics due to its photoprotective potential.
82
© Sabinsa Corporation 2011| www.sabinsa.com
OXYRESVENOX™ – Oxyresveratrol
• OxyResvenox™ is the registered trademark of Sabinsa’s Oxyresveratrol.
• Oxyresveratrol is the analog of Resveratrol and is of synthetic Origin.
• Sabinsa's 34th US Patent 7,253,324, specifically protects the process for the synthesis of biologically active polyphenolic compounds like Pterostilbene, Resveratrol, Oxyresveratrol and Gnetol.
CH CH
O H
O H
OH
HO
I
83
© Sabinsa Corporation 2011| www.sabinsa.com
Dose-dependent inhibitory effects on mushroom tyrosinase by Oxyresveratrol,
Resveratrol, and Kojic acid.
A – Oxyresveratrol B - Resveratrol C – Kojic Acid
Lower the IC50 value Better the activity84
IC5
0 (
M)
© Sabinsa Corporation 2011| www.sabinsa.com 85
SabiLize (Natural Preservatives)
A natural proprietary preservative blend, under the brand name “SabiLize
“Helps Stabilize formulations the natural way”
SabiLize in creams are significantly effective against• Staphylococcus aureus (Gram positive bacteria) at
0.5% • Escherichia coli (Gram negative bacteria) at 0.5% • Candida albicans (Yeast) at 0.5% • Aspergillus niger (Filamentous fungi) at 1.0%
Ocular and Dermal Irritection Assays classified that SabiLize is,
Minimal irritant for ocular irritation potential Non irritant for dermal irritation potential
© Sabinsa Corporation 2011| www.sabinsa.com 86
© Sabinsa Corporation 2011| www.sabinsa.com
3’- Hydroxypterostilbene (3’-HPT)
• 3’-Hydroxypterostilbene is a stilbene isolated from Pterocarpus marsupium, Sphaerophysa salsula and certain types of propolis.
• It is an analog of Resveratrol and Pterostilbene.
• 3’-HPT is about 30 times more potent antioxidant than Resveratrol, 70 times than vitamin E, 80 times than vitamin C, 90 times than BHT.
• Potent skin lightening agent.
• Supports weight management.
• Supports general health and wellness.
87
© Sabinsa Corporation 2011| www.sabinsa.com
Turmerones• Sabinsa’s Turmerone is a powdered standardized
extract from the dried rhizomes of Curcuma longa and contains a minimum of 25% Turmerones.
• Turmeric root contains 5 -6% of Turmeric oil.
• The chief components of Turmeric oil are sesquiterpene ketones (50 – 60%) in the form of
Turmerone and ar-Turmerone.
• Potent anti-inflammatory and anti-arthritis agent.
Ar-Turmerone
88
© Sabinsa Corporation 2011| www.sabinsa.com 89
Arthritis, joint health,
inflammation
Osteoporosis
Abnormal blood lipid levels
Hyperglycemia
Cardiovascular health
Prostate health
Menopausal symptoms
Obesity
Cancer/chronic disease
prevention
NUTRACEUTICALS – COMMON HEALTH CONCERNS ADDRESSED
© Sabinsa Corporation 2011| www.sabinsa.com 90
Skin Lightening
Sunless tanning
UV protection
Antioxidants & Anti inflammatory
Anti Ageing
Wound Healing
Sebum Regulation
Barrier function restoration
Anti Cellulite
Stretch marks prevention
Hair fall prevention
COSMECEUTICALS – COMMON COSMETIC CONCERNS ADDRESSED
© Sabinsa Corporation 2011| www.sabinsa.com
Always on the Trail of New Products…
New Developments..New Applications…
91
• Broad Institute (Harvard & MIT) discovered Piperlongumine has an unique anticancer mechanism (Nature July 2011, 475, 231-4)•Piperlongumine increases Reactive Oxygen Species selectively in cancer cells, thus killing them, compared to normal cells •Piperlongumine occurs in Piper longum L•Piperlongumine already extracted by Sami Labs in multi-kg quantities •M D Anderson Cancer Center in Houston, USA is presently doing studies on anticancer application.
Exploring ways to reduce the burden of diseases
© Sabinsa Corporation 2011| www.sabinsa.com
Patent Awards
US Patent # 5,804,596, won the Thomas Alva Edison Patent Award (R & D Council, NJ USA) in 2004 for ForsLean
Thomas Alva Edison Patent Award 2005 for THP
Thomas Alva Edison Patent Award 2009 for Garcitrin
92
© Sabinsa Corporation 2011| www.sabinsa.com 93
U.S. & International Patents issued: 68
Patent Coverage: India, U.S.A., European Patent Office, Sweden, Netherlands, Italy, United Kingdom, Ireland, Luxembourg, Monaco, Portugal, Spain, France, Denmark, Greece, Switzerland, Belgium, Austria, Germany, Japan, Australia, New Zealand, Canada and Russia.
Intellectual Intellectual PropertyProperty
© Sabinsa Corporation 2011| www.sabinsa.com 94
Innovating for the Future from the Past…
© Sabinsa Corporation 2011| www.sabinsa.com 95
THANK YOUTHANK YOU
www.sabinsa.com
www.samilabs.com